Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) had its target price lowered by equities researchers at Chardan Capital from $5.00 to $4.00 in a report released on Wednesday, August 9th, MarketBeat.com reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Chardan Capital’s target price would indicate a potential downside of 14.44% from the company’s previous close.
Other research analysts have also recently issued reports about the company. Maxim Group decreased their price objective on Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, April 25th. BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Jefferies Group LLC restated a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Finally, Robert W. Baird upped their price target on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, April 24th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.25.
Shares of Achillion Pharmaceuticals (ACHN) opened at 4.67 on Wednesday. The stock’s market cap is $638.67 million. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $9.49. The company has a 50-day moving average price of $4.45 and a 200 day moving average price of $4.16.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same period last year, the firm earned ($0.14) earnings per share. Equities research analysts expect that Achillion Pharmaceuticals will post ($0.63) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Price Target Lowered to $4.00 at Chardan Capital” was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/achillion-pharmaceuticals-inc-nasdaqachn-pt-lowered-to-4-00-at-chardan-capital-updated.html.
Several hedge funds have recently made changes to their positions in ACHN. EcoR1 Capital LLC bought a new stake in shares of Achillion Pharmaceuticals during the second quarter valued at about $3,410,000. DAFNA Capital Management LLC boosted its stake in shares of Achillion Pharmaceuticals by 35.6% in the second quarter. DAFNA Capital Management LLC now owns 266,500 shares of the biopharmaceutical company’s stock valued at $1,223,000 after buying an additional 70,000 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Achillion Pharmaceuticals during the second quarter valued at about $20,778,000. QS Investors LLC boosted its stake in shares of Achillion Pharmaceuticals by 36.4% in the second quarter. QS Investors LLC now owns 378,570 shares of the biopharmaceutical company’s stock valued at $1,738,000 after buying an additional 101,018 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in shares of Achillion Pharmaceuticals by 13.7% in the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 6,730 shares during the last quarter. Institutional investors and hedge funds own 70.70% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.